Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-26

Clinical Trial Update: Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated pegloticase in adults with uncontrolled gout who have had a kidney transplant; results were posted in July 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KRYSTEXXA (pegloticase)

Snippet

Sponsor: Amgen | Conditions: Uncontrolled Gout, Kidney Transplant | Phase 4 | Status: COMPLETED | Results posted: 2022-07-26